<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803059</url>
  </required_header>
  <id_info>
    <org_study_id>Bellmed002</org_study_id>
    <nct_id>NCT03803059</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of SkinPen on Male and Female Subjects' Fine Lines and Wrinkles of the Face and Neck</brief_title>
  <official_title>A Single-Center Trial to Evaluate the Efficacy and Tolerability of SkinPen on Male and Female Subjects' Fine Lines and Wrinkles of the Face and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Medical, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, clinical trial is being conducted over the course of 90 days followed by&#xD;
      1-month and 6-month post-treatment visits in order to assess the efficacy and tolerability of&#xD;
      the Sponsor's SkinPen device when used by men and women with fine lines and wrinkles of the&#xD;
      face and neck.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of fine lines and wrinkles severity</measure>
    <time_frame>6 months</time_frame>
    <description>A modified Griffith's 10-point scale from 0 to 9. 0 indicates none (best possible condition), while 9 indicates severe (worst possible condition.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of fine lines and wrinkles severity</measure>
    <time_frame>6 months</time_frame>
    <description>The Fitzpatrick Wrinkle Classification System (FWCS) from 0 to 9. 0 indicates no fine lines or wrinkles, while 9 indicates significant (severe) fine lines or wrinkles observable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aesthetic improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Global Aesthetic improvement assessment from 1 to 5. 1 indicates Very Much Improved: Optimal cosmetic result in this subject, while 5 indicates Worse: the appearance is worse than the original condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin thickness</measure>
    <time_frame>6 months</time_frame>
    <description>OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin density</measure>
    <time_frame>6 months</time_frame>
    <description>Ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin firmness</measure>
    <time_frame>6 months</time_frame>
    <description>BTC 2000</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrity of the stratum corneum</measure>
    <time_frame>6 months</time_frame>
    <description>TEWL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Wrinkle</condition>
  <condition>Fine Lines</condition>
  <arm_group>
    <arm_group_label>Fine lines and wrinkles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microneedle treatment to face and neck areas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SkinPen Precision</intervention_name>
    <description>Surgical instrument motors and accessories/attachments/Hydrogel</description>
    <arm_group_label>Fine lines and wrinkles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 20% of subjects will have Fitzpatrick skin types IV-VI&#xD;
&#xD;
          -  Individuals who grade a 4 or higher on the Fitzpatrick Wrinkle Scale&#xD;
&#xD;
          -  Individuals that desire correction of their fine lines and wrinkles&#xD;
&#xD;
          -  Individuals willing to withhold aesthetic therapies to the areas of the face and neck&#xD;
             being treated or judged to potentially impact results by the Investigator.&#xD;
&#xD;
          -  Women of child bearing potential agree to take a urine pregnancy test at the Baseline&#xD;
             visit and 6-months post-treatment or when deemed by Investigator and/or Sponsor. This&#xD;
             may be changed to one month pregnancy test at the Sponsor's discretion. Women who are&#xD;
             of childbearing potential must have a negative urine pregnancy test result and must&#xD;
             not be lactating at the baseline visit. Women must be willing and able to use an&#xD;
             acceptable method of birth control (e.g. barrier methods used with a spermicidal&#xD;
             agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study.&#xD;
             Women will not be considered of childbearing potential if one of the following&#xD;
             conditions is documented on the medical history:&#xD;
&#xD;
               -  Postmenopausal for at least 12 months prior to study;&#xD;
&#xD;
               -  Without a uterus and/or both ovaries;&#xD;
&#xD;
               -  Bilateral tubal ligation at least 6 months prior to study enrollment.&#xD;
&#xD;
          -  Women of child bearing potential agree to take a urine pregnancy test at the Baseline&#xD;
             visit and 6-months post-treatment or when deemed by Investigator and/or Sponsor. This&#xD;
             may be changed to one month pregnancy test at the Sponsor's discretion. Women who are&#xD;
             of childbearing potential must have a negative urine pregnancy test result and must&#xD;
             not be lactating at the baseline visit. Women must be willing and able to use an&#xD;
             acceptable method of birth control (e.g. barrier methods used with a spermicidal&#xD;
             agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study.&#xD;
             Women will not be considered of childbearing potential if one of the following&#xD;
             conditions is documented on the medical history:&#xD;
&#xD;
               -  Postmenopausal for at least 12 months prior to study;&#xD;
&#xD;
               -  Without a uterus and/or both ovaries;&#xD;
&#xD;
               -  Bilateral tubal ligation at least 6 months prior to study enrollment.&#xD;
&#xD;
          -  Individuals of child baring potential who use an acceptable method of contraception&#xD;
             throughout the study. Acceptable methods of birth control include:&#xD;
&#xD;
               1. Established use of hormonal methods of contraception (oral, injected, implanted,&#xD;
                  patch or vaginal ring).&#xD;
&#xD;
               2. Barrier methods of contraception with spermicide: condom or occlusive cap&#xD;
                  (diaphragm or cervical/vault caps) with spermicidal&#xD;
                  foam/gel/film/cream/suppository.&#xD;
&#xD;
               3. Intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
               4. Surgical sterilization (e.g., vasectomy that has been confirmed effective by&#xD;
                  sperm count check, tubal occlusion, hysterectomy, bilateral&#xD;
                  salpingectomy/oophorectomy)&#xD;
&#xD;
               5. Abstinence from heterosexual intercourse, when this is in line with the preferred&#xD;
                  and usual lifestyle of the subject. Periodic abstinence (e.g., calendar,&#xD;
                  ovulation, symptothermal, post-ovulation methods) and withdrawal are not&#xD;
                  acceptable methods of contraception.&#xD;
&#xD;
          -  Individuals that are willing to provide written informed consent and are able to read,&#xD;
             speak, write, and understand English.&#xD;
&#xD;
          -  Individuals willing to sign a photography release.&#xD;
&#xD;
          -  Willingness to cooperate and participate by following study requirements (including&#xD;
             those outlined in section 5.5) for the duration of the study and to report any changes&#xD;
             in health status or medications, adverse event symptoms, or reactions immediately.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals diagnosed with known allergies to facial or general skin care products.&#xD;
&#xD;
          -  Individuals who have presence of an active systemic or local skin disease that may&#xD;
             affect wound healing.&#xD;
&#xD;
          -  Individuals who have severe solar elastosis.&#xD;
&#xD;
          -  Individuals with sensitivity to topical lidocaine.&#xD;
&#xD;
          -  Individuals who have physical or psychological conditions unacceptable to the&#xD;
             Investigator.&#xD;
&#xD;
          -  Individuals who have a recent history of significant trauma to the areas to be treated&#xD;
             (&lt; 6 months).&#xD;
&#xD;
          -  Individuals who have significant scarring, other than acne scars, in the area(s) to be&#xD;
             treated.&#xD;
&#xD;
          -  Individuals who have severe or cystic active and clinically significant acne on the&#xD;
             area(s) to be treated. Clinically significant acne is defined as a subject whom has &gt;&#xD;
             5 active inflammatory acne lesions (including acne conglobate, nodules, or cysts) in&#xD;
             either the right or left treatment area.&#xD;
&#xD;
          -  Individuals who have a recent or current history of inflammatory skin disease,&#xD;
             infection, cancerous/pre-cancerous lesion, unhealed wound or clinically significant&#xD;
             acne in the proposed treatment areas. Individuals who have a history of systemic&#xD;
             granulomatous diseases, active or inactive, (e.g. Sarcoid, Wegeners, TB, etc.) or&#xD;
             connective tissue diseases (e.g. lupus, dermatomyositis, etc.).&#xD;
&#xD;
          -  Individuals who currently have or have a history of hypertrophic scars, or keloid&#xD;
             scars.&#xD;
&#xD;
          -  Individuals who currently have cancerous or pre-cancerous lesions in the areas to be&#xD;
             treated and/or with a history of skin cancer.&#xD;
&#xD;
          -  Individuals who have the inability to understand instructions or to give informed&#xD;
             consent.&#xD;
&#xD;
          -  Individuals who have had microdermabrasion or glycolic acid treatment to the treatment&#xD;
             area(s) within 1 month prior to study participation or who will have this treatment&#xD;
             during the study.&#xD;
&#xD;
          -  Individuals who have a history of chronic drug or alcohol abuse.&#xD;
&#xD;
          -  Individuals undergoing concurrent therapy that, in the Investigator's opinion, would&#xD;
             interfere with the evaluation of the safety or efficacy of the study device.&#xD;
&#xD;
          -  Individuals who, in the Investigator's opinion, have a history of poor cooperation,&#xD;
             noncompliance with medical treatment, or unreliability.&#xD;
&#xD;
          -  Individuals who are current smokers or have smoked in the last 5 years.&#xD;
&#xD;
          -  Individuals who have a history of the following cosmetic treatments in the area(s) to&#xD;
             be treated:&#xD;
&#xD;
               -  Skin tightening procedure within the past year;&#xD;
&#xD;
               -  Injectable filler of any type within the past:&#xD;
&#xD;
                    -  12 months for Hyaluronic acid fillers (e.g. Restylane)&#xD;
&#xD;
                    -  12 months for Ca Hydroxyapatite fillers (e.g. Radiesse)&#xD;
&#xD;
                    -  24 months for Poly-L-Lactic acid fillers (e.g. Sculptra)&#xD;
&#xD;
                    -  Ever for permanent fillers (e.g. Silicone, ArteFill)&#xD;
&#xD;
               -  Neurotoxins within the past 3 months;&#xD;
&#xD;
               -  Ablative resurfacing laser treatment;&#xD;
&#xD;
               -  Non-ablative, rejuvenative laser or light treatment within the past 6 months;&#xD;
&#xD;
               -  Surgical dermabrasion or deep facial peels;&#xD;
&#xD;
               -  Had a chemical peel, dermabrasion, non-ablative laser or fractional laser&#xD;
                  resurfacing of the face and neck within 4 weeks&#xD;
&#xD;
          -  Individuals with a history of using the following prescription medications:&#xD;
&#xD;
               -  Accutane or other systemic retinoids within the past 6 months;&#xD;
&#xD;
               -  Topical Retinoids within the past 2 weeks;&#xD;
&#xD;
               -  Prescription strength skin lightening devices (e.g. hydroquinone, tretinoin, AHA,&#xD;
                  BHA and polyhydroxy acids, 4-hydroxyanisole alone or in combination with&#xD;
                  tretinoin, etc.) within 4 months;&#xD;
&#xD;
               -  Any anti-wrinkle, skin lightening devices, or any other device or topical or&#xD;
                  systemic medication known to affect skin aging or dyschromia (devices containing&#xD;
                  alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or&#xD;
                  licorice extract (topically), Tego® Cosmo C250, gigawhite, lemon juice extract&#xD;
                  (topically), emblica extract, etc.) within 2 weeks;&#xD;
&#xD;
               -  Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix, chronic NSAID&#xD;
                  use); and/or&#xD;
&#xD;
               -  Psychiatric drugs that in the Investigator's opinion would impair the subject&#xD;
                  from understanding the protocol requirements or understanding and signing the&#xD;
                  informed consent.&#xD;
&#xD;
          -  Individuals who are nursing, pregnant, or planning to become pregnant during the study&#xD;
             according to subject self-report.&#xD;
&#xD;
          -  Individuals having a health condition and/or pre-existing or dormant dermatologic&#xD;
             disease on the face or body (e.g., psoriasis, rosacea, eczema, seborrheic dermatitis,&#xD;
             vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory&#xD;
             hyperpigmentation) that the Investigator or designee deems inappropriate for&#xD;
             participation or could interfere with the outcome of the study.&#xD;
&#xD;
          -  Individuals with a history of immunosuppression/immune deficiency disorders (including&#xD;
             HIV infection or AIDS) or currently using immunosuppressive medications (e.g.,&#xD;
             azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate&#xD;
             mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined&#xD;
             by study documentation.&#xD;
&#xD;
          -  Individuals with an uncontrolled disease such as asthma, diabetes, hyperthyroidism,&#xD;
             medically significant hypertension or hypothyroidism. Individuals having multiple&#xD;
             health conditions may be excluded from participation even if the conditions are&#xD;
             controlled by diet, medication, etc.&#xD;
&#xD;
          -  Individuals with any planned surgeries, overnight hospitalization, and/or invasive&#xD;
             medical procedures during the course of the study.&#xD;
&#xD;
          -  Individuals who are currently participating in any other study involving the use of&#xD;
             investigational devices or drugs or have participated in any clinical trial at UT&#xD;
             Southwestern or at another research facility or doctor's office within 4 weeks prior&#xD;
             to inclusion into the study.&#xD;
&#xD;
          -  Individuals who have observable suntan, nevi, excessive hair, etc. or other dermal&#xD;
             conditions on the face and neck that might influence the test results in the opinion&#xD;
             of the Investigator or designee.&#xD;
&#xD;
          -  Individuals who have any condition, which in the opinion of the Investigator makes the&#xD;
             patient unable to complete the study per protocol (e.g. patients not likely to avoid&#xD;
             other facial cosmetic treatments; patients not likely to stay in the study for its&#xD;
             duration because of other commitments, concomitant conditions, or past history;&#xD;
             patients anticipated to be unreliable, or patients who have a concomitant condition&#xD;
             that may develop symptoms that might confuse or confound study treatments or&#xD;
             assessments).&#xD;
&#xD;
          -  Individuals who started hormone replacement therapies (HRT) or hormones for birth&#xD;
             control less than 3 months prior to study entry or who plan on starting, stopping, or&#xD;
             changing doses of HRT or hormones for birth control during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Kenkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 6, 2021</submitted>
    <returned>July 30, 2021</returned>
    <submitted>October 6, 2021</submitted>
    <returned>November 3, 2021</returned>
    <submitted>November 3, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

